Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK4827 (brodalumab) in Palmoplantar Pustulosis
NCT04061252Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in palmoplantar pustulosis (PPP) comparing KHK4827 with Placebo (2 arms). Primary endpoint: Palmoplantar Pustulosis Area and Severity Index at 16 weeks. Started Aug 2019; status: completed.
02
Drugs
brodalumab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04061252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061252.